An extension of a multicenter, randomized, split-face clinical trial evaluating the efficacy and safety of chromophore gel-assited blue light phototherapy for the treatment of acne

NIKOLIS, A. ET AL., 2018

INTRODUCTION
Extension trial followed the Main trial (Antoniou et al. 2016) with two main objectives:
- Evaluate the efficacy of the biophotonic system on the untreated hemiface during the Main trial
- Evaluate the duration of response on the hemiface treated during the first 12-week Main trial

RESULTS

EFFICACY
At weeks 6 and 12 respectively success rate was measured for the different IGA patient groups (Fig.1):
- Patients baseline IGA = 2 (mild) on treated hemiface: success rate of 58.3 and 66.7%
- Patients baseline IGA = 3 (moderate): success rate of 81.8 and 90.0%
- Patients baseline IGA = 4 (severe): success rate of 100% at both weeks
In the per protocol population, at week 12, a decrease in at least 1 IGA grade (success) was observed in 92.3% of patients.

Fig 1. Proportion of patients with an improvement of at least 1 IGA grade over time at week 6 and 12

LONG-LASTING RESULTS
- 85.5% patients achieving success in the Main trial maintained it at week 24, confirming long duration of effect following treatment

SAFETY
“The patient safety profile was also excellent, with very few related adverse events.  “
“There was a decrease in the number of adverse events compared to the Main trial, even when the same investigators participated in both.  Might be by a learning curve in the use of the biophotonic system.”

CONCLUSIONS
- “Study confirmed the long duration of effect following treatment”
- “Patient safety profile was excellent, with very few related adverse events”
- “The biophotonic system provides long-term efficacy and safety in the treatment of acne vulgaris, with a rate of compliance above what is generally observed in a young population”